More maintenance.

Neoadjuvant, cisplatin-based chemotherapy is preferred for muscle invasive urothelial carcinoma (MIBC). he role of adjuvant therapy (including immunotherapy) is unclear. Recently, the phase 3 IMvigor010 found that up to 1 year of adjuvant atezolizumab (a PD-L1 inhibitor) did not improve disease-free survival in patients with high risk, resected muscle invasive urothelial carcinoma. In CheckMate 274, 709 patients with resected muscle invasive urothelial carcinoma (79% bladder cancer) were randomized to placebo or nivolumab (a PD-1 inhibitor) for up to 1 year. In the overall population, adjuvant nivolumab nearly doubled median disease-free survival (DFS) from 10.8→ 20.8 months and increased 6-month DFS from 60.3→ 74.9%. This was driven by significant improvements in survival free from recurrence outside the urothelial tract and distant metastasis. | Bajorin, N Engl J Med 2021


  1. This is another testimony on how Chief Dr Lucky cured my HIV disease. Do you need a cure for your HIV disease? Do you want to be cured from your cancer disease? Or you want to be free from any type of disease. Kindly visit his website . He just cured my HIV disease and I’m very grateful to him, he is the only herbalist that can cure you.  
    WhatsApp number : +2348132777335 
    Via Email :
    Thank you all for reading,
    God bless"

  2. This has been a really wonderful article. Many thanks for providing this information. Visit our website too girl kubet


Post a Comment

Popular Posts